Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 6/20 | 0.50 |
| ▸ | NPY4R | P50391 | 6/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.50 |
| ▸ | NPY1R | P25929 | 4/20 | 0.50 |
| ▸ | RAMP3 | O60896 | 7/20 | 0.50 |
| ▸ | CALCR | P30988 | 7/20 | 0.50 |
| ▸ | GLP1R | P43220 | 6/20 | 0.50 |
| ▸ | GIPR | P48546 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29353296 | 0.96 | NPY2R (0.47) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL29353374 | 0.95 | CTSD (0.47) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL29518457 | 0.93 | BACE1 (0.47) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL29855903 | 0.92 | NPY2R (0.53) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL30526237 | 0.92 | NPY2R (0.60) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL29424684 | 0.89 | RAMP3 (0.56) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL29479863 | 0.89 | NPY2R (0.52) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL30906558 | 0.88 | RAMP3 (0.47) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL30906409 | 0.88 | RAMP3 (0.47) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL30607399 | 0.88 | RAMP3 (0.50) | NPY2RNPY4RNPY5RNPY1RRAMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4879 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637661-B2 | Methods of enhancing stem cell differentiation into beta cells | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-05-26 | — | — | US | claimed |
| US-20260137642-A1 | METHODS OF TREATING PATIENTS HAVING TYPE 1 DIABETES WITH EFLORNITHINE | CANCER PREVENTION PHARMACEUTICALS, INC. (US) | 2026-05-21 | — | — | US | claimed |
| EP-3875959-B1 | C PEPTIDE DETECTION BY MASS SPECTROMETRY | QUEST DIAGNOSTICS INVEST LLC (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4744724-A2 | PEPTIDES AND METHODS FOR TREATING DISEASES | OP-T LLC (US) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099858-A1 | IMPROVED IG-LIKE FUSION PROTEINS FOR TREATING GRAVES DISEASE | CANOPY IMMUNO-THERAPEUTICS LTD. (IL) | 2026-05-15 | — | — | WO | claimed |
| US-20260130950-A1 | METHODS OF DELIVERY OF ISLET CELLS AND RELATED METHODS | SANA BIOTECHNOLOGY INC (US) | 2026-05-14 | — | — | US | claimed |
| US-20260128144-A1 | Systems and Methods for Pharmacotherapeutic Intervention in Obesity Treatment Targeting Multiple Neurophysiological Mechanisms Using Patient Phenotyping Modeling | INTELLIHEALTH INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4732297-A1 | TREATMENT DECISION SUPPORT FOR TREATMENT OF TYPE 2 DIABETES MELLITUS | OneTwo Analytics AB (SE) | 2026-04-29 | — | — | EP | claimed |
| US-20260104428-A1 | AUTOMATIC REVIEW METHOD FOR GLYCATED HEMOGLOBIN, SAMPLE ANALYSIS DEVICE, AND SAMPLE ANALYSIS SYSTEM | SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. (CN) | 2026-04-16 | — | — | US | claimed |
| EP-4726394-A1 | AUTOMATIC REVIEW METHOD FOR GLYCATED HEMOGLOBIN, SAMPLE ANALYSIS DEVICE, AND SAMPLE ANALYSIS SYSTEM | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (CN) | 2026-04-15 | — | — | EP | claimed |
| US-20220041720-A1 | Methods and Compositions for Preventing Type 1 Diabetes | YALE UNIVERSITY | 2022-02-10 | — | — | US | claimed |
| US-20220042971-A1 | METHODS FOR QUANTITATION OF INSULIN AND C-PEPTIDE | QUEST DIAGNOSTICS INVESTMENTS LLC (US) | 2022-02-10 | — | — | US | claimed |
| EP-3948294-A1 | USE OF FOLLISTATIN IN TYPE 2 DIABETES RISK PREDICTION | Lundoch Diagnostics AB (SE) | 2022-02-09 | — | — | EP | claimed |
| CN-114026225-A | Safe immunostealth cells | 诺和诺德股份有限公司 | 2022-02-08 | — | — | CN | claimed |
| CN-114026426-A | Use of follistatin in predicting risk of type 2 diabetes | 隆德诊断有限公司 | 2022-02-08 | — | — | CN | claimed |
| WO-2022026932-A2 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-02-03 | — | — | WO | claimed |
| WO-2022026933-A2 | IN VITRO DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-02-03 | — | — | WO | claimed |
| US-20220023269-A1 | Methods Of Treating Diabetes In Severe Insulin-Resistant Diabetic Subjects | BETAGENON AB (SE) | 2022-01-27 | — | — | US | claimed |
| WO-2022017309-A1 | INSULIN-FC FUSION PROTEIN AND APPLICATION THEREOF | 江苏晟斯生物制药有限公司 | 2022-01-27 | — | — | WO | claimed |
| CN-113968911-A | insulin-Fc fusion protein and application thereof | 江苏晟斯生物制药有限公司 | 2022-01-25 | — | — | CN | claimed |